On June 4th, Gelonghui announced that the Chinese phase I clinical trial of MRX-8, a new type of injectable polycillin-class antibacterial drug independently developed by the company, has been completed recently and achieved expected goals.
MRX-8 is an injectable polycillin-class antibacterial drug mainly used to treat multidrug-resistant gram-negative bacteria infections. Traditional polycillin-class drugs are clinically limited due to their potential for inducing frequent kidney toxicity and neurotoxicity. As a new type of polycillin-class cationic peptide drug, MRX-8 has undergone careful structural design and is expected to reduce the risk of polycillin antibacterial drug kidney toxicity and neurotoxicity while maintaining or improving treatment efficacy.